These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37307171)

  • 21. Design and synthesis of quinazoline-3,4-(4H)-diamine endowed with thiazoline moiety as new class for DPP-4 and DPPH inhibitor.
    Ali Z; Akhtar MJ; Haider MR; Khan AA; Siddiqui AA; Yar MS
    Bioorg Chem; 2017 Apr; 71():181-191. PubMed ID: 28215601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study on gluco-regulatory potential of glimepiride sulfonamide using in silico, in vitro and in vivo approaches.
    Parmar HS; Bhinchar MK; Bhatia M; Chordia N; Raval I; Chauhan DS; Manivannan E; Jatwa R; Kumar A
    Curr Pharm Des; 2014; 20(32):5212-7. PubMed ID: 24641189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DPP-IV Inhibitory Phenanthridines: Ligand, Structure-Based Design and Synthesis.
    Khalaf RA; Masalha D; Sabbah D
    Curr Comput Aided Drug Des; 2020; 16(3):295-307. PubMed ID: 30526469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid generation of novel benzoic acid-based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: Scaffold-hopping and prodrug study.
    Li Q; Meng L; Zhou S; Deng X; Wang N; Ji Y; Peng Y; Xing J; Yao G
    Eur J Med Chem; 2019 Oct; 180():509-523. PubMed ID: 31336309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and molecular docking studies of new aryl imeglimin derivatives as a potent antidiabetic agent in a diabetic zebrafish model.
    Khodakhah A; Mohammadi H; Abdoli S; Zarei I; Palimi M; Ekhtiari Z; Talebi M; Biglar M; Khorramizadeh MR; Amanlou M
    Sci Rep; 2024 Apr; 14(1):9410. PubMed ID: 38658742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antihyperglycemic activity with DPP-IV inhibition of alkaloids from seed extract of Castanospermum australe: Investigation by experimental validation and molecular docking.
    Bharti SK; Krishnan S; Kumar A; Rajak KK; Murari K; Bharti BK; Gupta AK
    Phytomedicine; 2012 Dec; 20(1):24-31. PubMed ID: 23063145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virtual Screening, Synthesis, and Biological Evaluation of Some Carbohydrazide Derivatives as Potential DPP-IV Inhibitors.
    Jadhav PB; Jadhav SB; Zehravi M; Mubarak MS; Islam F; Jeandet P; Khan SL; Hossain N; Rashid S; Ming LC; Sarker MMR; Azlina MFN
    Molecules; 2022 Dec; 28(1):. PubMed ID: 36615348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
    Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
    Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors.
    Li Q; Zhou M; Han L; Cao Q; Wang X; Zhao L; Zhou J; Zhang H
    Chem Biol Drug Des; 2015 Oct; 86(4):849-56. PubMed ID: 25787859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, evaluation and molecular docking of prolyl-fluoropyrrolidine derivatives as dipeptidyl peptidase IV inhibitors.
    Sharma M; Gupta M; Singh D; Kumar M; Kaur P
    Chem Biol Drug Des; 2013 Aug; 82(2):156-66. PubMed ID: 23581745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. α-Amylase and dipeptidyl peptidase-4 (DPP-4) inhibitory effects of
    Quek A; Kassim NK; Lim PC; Tan DC; Mohammad Latif MA; Ismail A; Shaari K; Awang K
    Pharm Biol; 2021 Dec; 59(1):964-973. PubMed ID: 34347568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nitrothiadiazolo[3,2-a]pyrimidines as promising antiglycating agents.
    Savateev K; Fedotov V; Butorin I; Eltsov O; Slepukhin P; Ulomsky E; Rusinov V; Litvinov R; Babkov D; Khokhlacheva E; Radaev P; Vassiliev P; Spasov A
    Eur J Med Chem; 2020 Jan; 185():111808. PubMed ID: 31683103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes.
    Kushwaha RN; Srivastava R; Mishra A; Rawat AK; Srivastava AK; Haq W; Katti SB
    Chem Biol Drug Des; 2015 Apr; 85(4):439-46. PubMed ID: 25216392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Encapsulation and Assessment of Antidiabetic Potential of α-Lactalbumin-Derived Hydrolysates.
    Puri B; Meena S; Kumar M H S; Shelke PA; Sabikhi L; Ashutosh
    J Agric Food Chem; 2023 Apr; 71(14):5547-5553. PubMed ID: 36989115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surrogating and redirection of pyrazolo[1,5-a]pyrimidin-7(4H)-one core, a novel class of potent and selective DPP-4 inhibitors.
    Deng X; Shen J; Zhu H; Xiao J; Sun R; Xie F; Lam C; Wang J; Qiao Y; Tavallaie MS; Hu Y; Du Y; Li J; Fu L; Jiang F
    Bioorg Med Chem; 2018 Feb; 26(4):903-912. PubMed ID: 29373269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure based virtual screening of MDPI database: discovery of structurally diverse and novel DPP-IV inhibitors.
    Tanwar O; Tanwar L; Shaquiquzzaman M; Alam MM; Akhter M
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3447-51. PubMed ID: 24948564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors.
    Li Q; Han L; Zhang B; Zhou J; Zhang H
    Org Biomol Chem; 2016 Oct; 14(40):9598-9611. PubMed ID: 27714283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo.
    Someya Y; Tahara A; Nakano R; Matsuyama-Yokono A; Nagase I; Fukunaga Y; Takasu T; Hayakawa M; Shibasaki M
    Naunyn Schmiedebergs Arch Pharmacol; 2008 May; 377(3):209-17. PubMed ID: 18398600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
    Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel 4-heteroaryl-antipyrines as DPP-IV inhibitors.
    Gomha SM; Eldebss TM; Badrey MG; Abdulla MM; Mayhoub AS
    Chem Biol Drug Des; 2015 Nov; 86(5):1292-303. PubMed ID: 26032047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.